Immunization of cats to induce neutralizing antibodies against Fel d 1, the major feline allergen in human subjects.
Fel d 1
antibody
cat allergy
vaccine
virus-like particle
Journal
The Journal of allergy and clinical immunology
ISSN: 1097-6825
Titre abrégé: J Allergy Clin Immunol
Pays: United States
ID NLM: 1275002
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
15
06
2018
revised:
18
01
2019
accepted:
23
01
2019
pubmed:
6
5
2019
medline:
19
5
2020
entrez:
7
5
2019
Statut:
ppublish
Résumé
Cat allergy in human subjects is usually caused by the major cat allergen Fel d 1 and is found in approximately 10% of the Western population. Currently, there is no efficient and safe therapy for cat allergy available. Allergic patients usually try to avoid cats or treat their allergy symptoms. We developed a new strategy to treat Fel d 1-induced allergy in human subjects by immunizing cats against their own major allergen, Fel d 1. A conjugate vaccine consisting of recombinant Fel d 1 and a virus-like particle derived from the cucumber mosaic virus containing the tetanus toxin-derived universal T-cell epitope tt830-843 (CuMV The vaccine was well tolerated and had no overt toxic effect. All cats induced a strong and sustained specific IgG antibody response. The induced anti-Fel d 1 antibodies were of high affinity and exhibited a strong neutralization ability tested both in vitro and in vivo. A reduction in the endogenous allergen level and a reduced allergenicity of tear samples, were observed. Vaccination of cats with Fel-CuMV
Sections du résumé
BACKGROUND
Cat allergy in human subjects is usually caused by the major cat allergen Fel d 1 and is found in approximately 10% of the Western population. Currently, there is no efficient and safe therapy for cat allergy available. Allergic patients usually try to avoid cats or treat their allergy symptoms.
OBJECTIVE
We developed a new strategy to treat Fel d 1-induced allergy in human subjects by immunizing cats against their own major allergen, Fel d 1.
METHODS
A conjugate vaccine consisting of recombinant Fel d 1 and a virus-like particle derived from the cucumber mosaic virus containing the tetanus toxin-derived universal T-cell epitope tt830-843 (CuMV
RESULTS
The vaccine was well tolerated and had no overt toxic effect. All cats induced a strong and sustained specific IgG antibody response. The induced anti-Fel d 1 antibodies were of high affinity and exhibited a strong neutralization ability tested both in vitro and in vivo. A reduction in the endogenous allergen level and a reduced allergenicity of tear samples, were observed.
CONCLUSION
Vaccination of cats with Fel-CuMV
Identifiants
pubmed: 31056187
pii: S0091-6749(19)30349-5
doi: 10.1016/j.jaci.2019.01.050
pii:
doi:
Substances chimiques
Allergens
0
Antibodies, Neutralizing
0
Glycoproteins
0
Immunoglobulin G
0
Recombinant Proteins
0
Vaccines
0
Fel d 1 protein, Felis domesticus
G408EE88II
Types de publication
Clinical Trial, Veterinary
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
193-203Informations de copyright
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.